Komipharm International Co., Ltd. (KOSDAQ:041960)
6,650.00
-100.00 (-1.48%)
Sep 18, 2025, 2:40 PM KST
Komipharm International Revenue
Komipharm International had revenue of 13.68B KRW in the quarter ending June 30, 2025, a decrease of -28.59%. This brings the company's revenue in the last twelve months to 54.81B, up 6.68% year-over-year. In the year 2024, Komipharm International had annual revenue of 58.78B with 37.83% growth.
Revenue (ttm)
54.81B
Revenue Growth
+6.68%
P/S Ratio
8.84
Revenue / Employee
340.45M
Employees
161
Market Cap
484.75B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 58.78B | 16.13B | 37.83% |
Dec 31, 2023 | 42.65B | 2.85B | 7.15% |
Dec 31, 2022 | 39.80B | 3.95B | 11.03% |
Dec 31, 2021 | 35.85B | -1.31B | -3.53% |
Dec 31, 2020 | 37.16B | 1.67B | 4.71% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Samsung Biologics | 5,031.69B |
Celltrion | 3,748.95B |
ALTEOGEN | 158.06B |
Yuhan | 2,165.44B |
SK Biopharmaceuticals | 620.28B |
Peptron | 5.18B |
PharmaResearch | 449.81B |
ABL Bio | 94.93B |